Sakthivel, K M and Rasmia, Rajan Radha (2020) NF-κB inhibitors in treatment and prevention of lung cancer. Biomedicine & Pharmacotherapy, 130. pp. 1-10. ISSN 0753-3322

[thumbnail of 40.Nfkb rash article-min.pdf] Text
40.Nfkb rash article-min.pdf - Published Version
Download (621kB)

Abstract

Intracellular signalling pathways have provided excellent resource for drug development particularly in the
development of cancer therapeutics. A wide variety of malignancies common in human exhibit aberrant NF-κB
constitutive expression which results in tumorigenic processes and cancer survival in a variety of solid tumour,
including pancreatic cancer, lung, cervical, prostate, breast and gastric carcinoma. Numerous evidences indicate
that NF-κB signalling mechanism is mainly involved in the progression of several cancers which may intensify an
enhanced knowledge on its role in disease particularly lung tumorigenesis. This has led to tremendous research
in designing a variety of NF-κB antagonists with enhanced clinical applications through different approaches the
most common being suppression of IκB kinase (IKK) beta activity. Many NF-κB inhibitors for lung cancer are now
under clinical trials. Preliminary results of clinical trials for several of these agents include small-molecule inhibitors and monoclonal antibodies. A few combinatorial treatment therapies are currently under investigation
in the clinics and have shown promise, particularly NF-κB inhibition associated with lung cancer

Item Type: Article
Uncontrolled Keywords: NF-κB Antagonists Signalling pathways Drug development Lung tumorigenesis
Depositing User: Mr Team Mosys
Date Deposited: 21 Jul 2022 07:41
Last Modified: 21 Jul 2022 07:41
URI: http://ir.psgcas.ac.in/id/eprint/1332

Actions (login required)

View Item
View Item
Altmetric